SynthesisFrontiers in pharmacology2026
Association between leukotriene receptor antagonists and neuropsychiatric disorders: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intrinsic AIE drug nanocrystals enable imaging-guided orchitis theranostics.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study conducted a meta-analysis of previous research to comprehensively evaluate the association between leukotriene receptor antagonists (LTRAs) and the risk of neuropsychiatric disorders, with a specific focus on examining potential variations in this association across different age groups. Methods: A comprehensive search was conducted across multiple databases, including PubMed, Embase, Web of Science and the Cochrane Library, from their inception until 28 April 2025, with no language restrictions applied. The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Data analysis was performed using R (version 4.2.2), with results expressed as relative risk (RR) and 95% confidence intervals (CI). Sensitivity analysis was carried out to verify the robustness of the findings. Heterogeneity was quantified using the I Results: A meta-analysis of the 21 included studies revealed a borderline non-significant association between LTRA use and neuropsychiatric risk in the overall population (RR = 1.11, 95% CI: 0.98-1.26). However, subgroup analysis indicated a statistically significant age-dependent disparity in this risk. Specifically, no significant increase in overall risk was observed in the pediatric population (RR = 1.12, 95% CI: 0.90-1.39). In contrast, a statistically significant positive association was identified in the adult population (RR = 1.30, 95% CI: 1.08-1.56). Conclusion: Our findings indicated that LTRA use was associated with a favorable neuropsychiatric safety profile in the pediatric population, but was linked to an increased risk in adults. These results highlighted the need for age-specific risk assessment in clinical management. Systematic Review Registration: CRD420251042206.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.